New potential therapy targets, such as inhibitors of CDK4/6, MDM2/p53, c-KIT, PI3K/Akt/mTOR, ERK, or IDH1, have also been considered for melanoma treatment27,28,44. This evidence concerns the gene MDM2 and melanoma.